You knew a better sampler had to exist.
Now it does.

The only endometrial sampler to combine suction, disruption, and absorption — supporting earlier, more accurate cancer detection, even before symptoms appear.*

*The Utepreva Endometrial Sampler (UP01) is used to obtain endometrial cytological and histological samples.

THE PROBLEM

Built to catch what others miss

The standard biopsy gets it wrong in 1 in 3 procedures.1 Utepreva combines three mechanisms to cover more of the uterine surface — for a larger, higher quality sample.

94%

Sensitivity for
endometrial cancer²

From a single, in-office procedure.

67%

More tissue
collected³

Than a leading sampler. 

Independently tested. Statistically significant.

3

Supported analyses 

in a single sample

One sample: three collection methods

THE PROBLEM

One sampler.
Three distinct mechanisms.

Utepreva's design combines three complementary mechanisms of action — collecting more from a single endometrial sample than any single method alone.

an endometrial sampler

Suction
Draws tissue directly into the collection chamber for immediate capture

Absorption
Retains cellular material across the full brush length — not just the tip

Disruption
Loosens endometrial tissue to maximize what’s collected.

an endometrial sampler

Absorption

Retains cellular material across the full brush length — not just the tip

Disruption

Loosens endometrial tissue to maximize what’s collected.

Suction
Draws tissue directly into the collection chamber for immediate capture

Portrait of founder and CEO Dr. Jeanetta Stega
THE PROBLEM
“I knew relying on multiple devices to obtain an adequate sample did not serve my patients well. So I designed a tool that incorporates three mechanisms of action to support effective tissue collection in one single procedure.”

After decades in the OR, Dr. Jeanetta Stega had seen thousands of times how an inadequate sample could cost a patient.

So she built the solution.

Meet the team
Red arrow pointing to the right
OUR MISSION

We exist to give every woman a fighting chance against uterine cancer.

Uterine cancer is one of the only cancers in America where mortality is still climbing. We believe that's not acceptable. Utepreva is built with clinical precision — and a fierce commitment to the women it serves.

Learn more about our mission
Red arrow pointing right.
68,270

U.S. cases estimated in 20264

14,450

Deaths expected this year5

2x

Mortality rate for Black women vs. white6

1.7%

Annual increase in death rate since the mid-2000s7

FOR CLINICIANS

Try Utepreva in your practice

And improve endometrial cancer diagnoses, one sampler at a time.

State
Thank you for your interest in Utepreva. Your name is on the waitlist to receive a sample — we'll be in touch soon. Together, let's make endometrial cancer detection more accessible.
Oops! Something went wrong while submitting the form.